Quantitative DCE-MRI modeling on tumor diagnosis and treatment effect evaluation

Dynamic contrast enhanced (DCE) MRI is the method of choice for clinical tumor detection. There are three categories of DCE-MRI analysis methods including qualitative DCE-MRI, semi-quantitative DCE-MRI, and quantitative DCE-MRI. Among these three categories, quantitative DCE-MRI is the only one that could provide pharmacokinetic parameters and directly reveal physiological state of tumor. In this paper, we have made a brief review on quantitative DCE-MRI. Firstly, physiological basis of DCE-MRI was described in details. Then, two kinds of contrast agent, low molecular weighted contrast media (LMCM) and macromolecular contrast media (MMCM), are introduced respectively. After that, several T1 weighted DCE-MRI data analysis methods are introduced, too. At last, possible further developments of DCE-MRI have been discussed.

[1]  A. Padhani.  Dynamic contrast‐enhanced MRI in clinical oncology: Current status and future directions , 2002, Journal of magnetic resonance imaging : JMRI.

[2]  A. Padhani,et al.  Reproducibility of dynamic contrast‐enhanced MRI in human muscle and tumours: comparison of quantitative and semi‐quantitative analysis , 2002, NMR in biomedicine.

[3]  Thomas E Yankeelov,et al.  Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology: Theory, Data Acquisition, Analysis, and Examples. , 2007, Current medical imaging reviews.

[4]  M. Giger,et al.  Automatic identification and classification of characteristic kinetic curves of breast lesions on DCE-MRI. , 2006, Medical physics.

[5]  Jürgen Hennig,et al.  Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. , 2005, European journal of cancer.

[6]  Paul S. Tofts,et al.  Quantitative MRI of the brain : measuring changes caused by disease , 2003 .

[7]  Benjamin M Yeh,et al.  Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[9]  B K Rutt,et al.  A fast 3D look-locker method for volumetric T1 mapping. , 1999, Magnetic resonance imaging.

[10]  I. Solomon,et al.  Nuclear Magnetic Interactions in the HF Molecule , 1956 .

[11]  A. Padhani,et al.  Reproducibility of quantitative dynamic MRI of normal human tissues , 2002, NMR in biomedicine.

[12]  Brandon Whitcher,et al.  Quantifying spatial heterogeneity in dynamic contrast‐enhanced MRI parameter maps , 2009, Magnetic resonance in medicine.

[13]  Lina Arbash Meinel,et al.  Breast MRI lesion classification: Improved performance of human readers with a backpropagation neural network computer‐aided diagnosis (CAD) system , 2007, Journal of magnetic resonance imaging : JMRI.

[14]  A. Jackson,et al.  Comparative study into the robustness of compartmental modeling and model‐free analysis in DCE‐MRI studies , 2006, Journal of magnetic resonance imaging : JMRI.

[15]  Areen K. Al-Bashir,et al.  New algorithm for quantifying vascular changes in dynamic contrast‐enhanced MRI independent of absolute T1 values , 2007, Magnetic Resonance in Medicine.

[16]  Tahsin Kurc,et al.  Malignant‐lesion segmentation using 4D co‐occurrence texture analysis applied to dynamic contrast‐enhanced magnetic resonance breast image data , 2007, Journal of magnetic resonance imaging : JMRI.

[17]  L. Turnbull,et al.  Textural analysis of contrast‐enhanced MR images of the breast , 2003, Magnetic resonance in medicine.

[18]  Kenya Murase,et al.  Efficient method for calculating kinetic parameters using T1‐weighted dynamic contrast‐enhanced magnetic resonance imaging , 2004, Magnetic resonance in medicine.

[19]  M. Knopp,et al.  Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.

[20]  J R Griffiths,et al.  Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. , 2003, The British journal of radiology.

[21]  J. Gore,et al.  Quantitative pharmacokinetic analysis of DCE-MRI data without an arterial input function: a reference region model. , 2005, Magnetic resonance imaging.